Pacritinib(Vonjo)

Pacritinib, an oral JAK2 inhibitor manufactured by Lucius Pharmaceuticals, provides a targeted treatment option for myelofibrosis patients with low platelet counts.

Summary of Key Information for Pacritinib.

Active Ingredient

Its main active ingredient is pacritinib.

Indicated Population

It is indicated for adult patients with intermediate- or high-risk primary or secondary myelofibrosis and low platelet counts.

Dosage and Administration

The recommended dose is 200 mg, administered orally twice daily, with or without food.

Use in Special Populations

Dose adjustment is required for patients with severe hepatic impairment. Patients with renal impairment should avoid the use of this drug. Men and women of reproductive potential, as well as lactating women, need to be aware of the relevant risks.

Drug Overdosage

Overdose may cause gastrointestinal reactions and myelosuppression, among other adverse effects. There is no specific antidote available.

Storage Conditions

Store in the original sealed packaging at room temperature below 30°C, protected from light.

Pharmacokinetics

This drug is mainly metabolized by CYP3A4, with a half-life of approximately 28 hours and a high average accumulation rate at steady state.

FDA，2025.10